Could inflammatory markers help diagnose nonalcoholic steatohepatitis?

被引:170
作者
Tarantino, Giovanni [1 ]
Conca, Paolo [1 ]
Pasanisi, Fabrizio [1 ]
Ariello, Manuela [1 ]
Mastrolia, Maria [1 ]
Arena, Adriano [1 ]
Tarantino, Marianna [3 ]
Scopacasa, Francesco [2 ]
Vecchione, Raffaela [4 ]
机构
[1] Univ Naples Federico II, Sch Med, Dept Clin & Expt Med, I-80131 Naples, Italy
[2] Univ Naples Federico II, Sch Med, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy
[3] Univ Naples Federico II, Sch Med, Dept Biomorphol & Funct Sci, I-80131 Naples, Italy
[4] Univ Naples Federico II, Sch Med, Inst Pathol, I-80131 Naples, Italy
关键词
IL-6; nonalcoholic fatty liver disease; spleen enlargement; ultrasonography; vascular endothelial growth factor; FATTY LIVER; HEPATIC STEATOSIS; SPLENIC VOLUME; OBESITY; SPLEEN; ANGIOGENESIS; ULTRASOUND; SIZE; INFILTRATION; ADIPOCYTES;
D O I
10.1097/MEG.0b013e3283229b40
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Nonalcoholic fatty liver disease describes a set of conditions that range from fatty liver to nonalcoholic steatohepatitis (NASH), and is considered the hepatic manifestation of metabolic syndrome. Obesity and insulin resistance are strongly associated with systemic markers of inflammation. Objective Focusing on this aspect, we have attempted to find a noninvasive method that could likely assess the presence of NASH and help to decide the liver biopsy performance. Methods Using histology as a gold standard to diagnose nonalcoholic fatty liver disease, we consecutively studied 43 patients with NASH and 40 with fatty liver, comparing their data with those of 48 healthy control participants. The outcomes evaluated were ultrasonographic spleen longitudinal diameter coupled with the splenic artery resistive index, serum IL-6 and vascular endothelial growth factor concentrations. Results The NASH group had higher spleen longitudinal diameter values (P=0.0001) as well as significantly higher IL-6 and vascular endothelial growth factor concentrations than the other groups (P=0.0001). The optimal cut-off value for spleen longitudinal diameter that best discriminated NASH from fatty liver patients was 116 mm (specificity 95% and sensitivity 88%); the sensitivity and specificity of this parameter was better than both IL-6 and vascular endothelial growth factor in the same setting (area under the receiver operating characteristic curve 0.920 vs. 0.817 and 0.678). Splenic artery resistive index was similar between patients with NASH and those with fatty liver, but differed when compared with controls, P=0.0001. Conclusions IL-6 was highly specific in confirming the absence of NASH at normal values. In our series, normal values of spleen longitudinal diameter and IL-6 were strongly associated with fatty liver. Eur J Gastroenterol Hepatol 21:504-511 (c) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:504 / 511
页数:8
相关论文
共 36 条
[1]  
Ataseven H, 2005, ACTA GASTRO-ENT BELG, V68, P221
[2]   NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[3]   Overall concordance correlation coefficient for evaluating agreement among multiple observers [J].
Barnhart, HX ;
Haber, M ;
Song, JL .
BIOMETRICS, 2002, 58 (04) :1020-1027
[4]  
Bolognesi M, 1996, HEPATOLOGY, V23, P1035
[5]   Liver volume and visceral obesity in women with hepatic steatosis undergoing gastric banding [J].
Busetto, L ;
Tregnaghi, A ;
De Marchi, F .
OBESITY RESEARCH, 2002, 10 (05) :408-411
[6]   Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma [J].
Caine, GJ ;
Lip, GYH ;
Stonelake, PS ;
Ryan, P ;
Blann, AD .
THROMBOSIS AND HAEMOSTASIS, 2004, 92 (01) :185-190
[7]  
Cicero Arrigo F G, 2006, Nutr Metab Cardiovasc Dis, V16, pe5, DOI 10.1016/j.numecd.2005.10.019
[8]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[9]   The clinicopathologic spectrum and management of nonalcoholic fatty liver disease [J].
Contos, MJ ;
Sanyal, TJ .
ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (01) :37-51
[10]  
Giles FJ, 2002, ONCOLOGY-NY, V16, P23